questionText: To ask the Secretary of State for Health and Social Care, whether (a) his Department, (b) his Department's agencies and (c) his Department's advisory bodies have made comparative assessments of the efficacy of (i) natalizumab Tysabri and (ii) natalizumab Tyruko for the treatment of multiple sclerosis.
answerText: Tyruko and Tysabri are United Kingdom licensed medicines. Tyruko is a biosimilar to the originator Tysabri. A biosimilar is a biological medicinal product that contains a version of the active substance of an already authorised original biological medicin...
heading: Multiple Sclerosis: Drugs